Storyline
Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal for in vivo cell therapy
Eli Lilly has agreed to acquire Kelonia Therapeutics, a cancer drug maker developing an in vivo CAR-T cell therapy currently in phase 1 trials for multiple myeloma. The deal is worth up to $7 billion, including $3.25 billion in upfront cash.
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.3 top sources shown
Overview
Eli Lilly has agreed to acquire Kelonia Therapeutics, a cancer drug maker developing an in vivo CAR-T cell therapy currently in phase 1 trials for multiple myeloma. The deal is worth up to $7 billion, including $3.25 billion in upfront cash.
Score total
1.56
Momentum 24h
3
Posts
3
Origins
3
Source types
2
Duplicate ratio
0%
Why now
- Kelonia's therapy is in early-phase clinical trials, making it a timely acquisition.
- Lilly is accelerating its investment in innovative cancer treatments this year.
- The deal follows Lilly's recent acquisition of another in vivo cell therapy company, signaling a trend.
Why it matters
- Strengthens Lilly's position in the emerging in vivo CAR-T therapy field.
- Targets multiple myeloma, a cancer with significant unmet medical need.
- Highlights Lilly's strategic focus on early-stage cell therapy development.
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: emerging_confirmed.
- Current status: open.
- 3 current source-linked posts are attached to this storyline.
All evidence
All evidence
BioPharma Dive
biopharmadive.com · biopharmadive.com · 2026-04-20 15:14 UTC
Fierce Biotech
fiercebiotech.com · fiercebiotech.com · 2026-04-20 14:18 UTC
CNBC
cnbc.com · cnbc.com · 2026-04-21 00:16 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)
- cnbc.com (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)
- cnbc.com (1)